Cargando…
Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
PROSPER is an international Phase III trial demonstrating the beneficial role of enzalutamide, an androgen receptor antagonist, in prolonging metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. The trial showed that the median metastasis-free survival was 21.9 mo...
Autores principales: | Rhea, Logan P, Gupta, Brinda, Aragon-Ching, Jeanny B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413545/ https://www.ncbi.nlm.nih.gov/pubmed/30460933 http://dx.doi.org/10.4103/aja.aja_88_18 |
Ejemplares similares
-
Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019) -
Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014) -
Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013) -
Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020) -
Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
por: El-Amm, Joelle, et al.
Publicado: (2013)